[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gut-microbiomes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gut-microbiomes":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,54,81,112,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":4},"100638239","dora---a-study-using-digital-health-toolsplatform-to-explore-the-impact-of-the-consumption-of-senior-milk-powder-containing-synbiotics-on-the-gut-microbiome-in-healthy-aging-individuals-100638239",false,"NCT07575529","DORA - A Study Using Digital Health Tools\u002FPlatform to Explore the Impact of the Consumption of Senior Milk Powder Containing Synbiotics on the Gut micRobiome in Healthy Aging Individuals","DORA - An Exploratory, Interventional Study Using Digital Health Tools and OneBiome to Explore the Impact of the Consumption of Senior Milk Powder Containing Synbiotics on the Gut micRobiome in Healthy Aging Individuals","DORA","Inclusion Criteria:\n\n1. Participants aged between 40 to 65 years (bounds included)\n2. Participants who are community-living\n3. Participants who are in good health (self-reported)\n4. Participants own and are willing to use their personal non-shared mobile device (iPhone 8 or later, with iOS version 16 or later), to pair with the study-provided Apple Watch SE, for the duration of the study\n5. Participant should be able to use mobile applications on smartphones to perform tasks in the study, have access to the internet and a smartphone or tablet to take and upload images and\u002For videos of stool, and other anatomical sites\n6. Participant should be able to comprehend the content of the study and to complete the study questionnaires in English\n7. Written and signed consent from participant\n8. Currently reside in Singapore and with the intention to reside in Singapore for at least the duration of the study.\n\nNote: Clinical trial participants may be permitted to undertake short-duration travel not exceeding 72 consecutive hours each time, provided such travel does not conflict with scheduled study visits, investigational product administration, or protocol-defined assessments. Prior notification to principal investigator or designated study personnel is required. The participant must be instructed on potential risks, adverse event reporting during the travel period.\n\nExclusion Criteria:\n\n1. Pregnant or lactating, or wish to become pregnant during the period of the study (self-reported)\n2. Participant with current or intended participation in a clinical study involving investigational or marketed products\n3. Use of named prebiotics, probiotics or synbiotics (in a capsule or sachet) within the last 4 weeks prior to screening or are planning to use it during the study including but not limited to the products listed below:\n\n   * BioGaia Probiotic Tablets\n   * LACTO FIT Probiotics\n   * Nano Singapore Digestive Wellness Formula\n   * California Gold Nutrition LactoBif Probiotics\n   * Life Space Probiotic\n   * Vivomixx 112.5 Billion Live Probiotics\n   * Duolac Daily Vitality Probiotic\n   * ATOMY Probiotics 10+\n   * Blackmores Ultra Max Probiotics+\n   * Holistic Way High Strength Probiotic 75 Billion\n4. Use of any commercial healthy aging milk powder within the last 4 weeks prior to screening or are planning to use it during the study including but not limited to:\n\n   * Boost Optimum\n   * Enercal complete\n   * Anlene\n   * Ensure\n5. Use of systemic antibiotics within the last 8 weeks prior to screening\n6. Known allergy or intolerance to Galactooligosaccharides (GOS), lactose, probiotics, or any ingredient in the SP\n7. Gastrointestinal (GI) surgery within the last 6 months prior to screening\n8. BMI below 18.5 kg\u002Fm² or above 27.5 kg\u002Fm²\n9. Participants who are using insulin, or have poorly controlled diabetes (HbA1c ≥ 10%) within last 3 months prior to screening\n10. Other severe disease(s) impairing activities of daily living or affecting the ability to complete the study assessments such as malignancy, end stage organ failure, COPD on long-term oxygen therapy, stroke with significantly residual functional weakness, cardiac failure with poor effort tolerance, significant neurological disease such as cognitive impairment from dementia, severe neuromuscular disease like Parkinson's disease, psychiatric disease\u002Fdisorder, auto-immune disease, allergic conditions requiring chronic systemic medication, other severe GI disease(s) such as Crohn's disease, GI cancer, or ulcerative colitis diagnosed by a physician\n11. History of drug abuse (Drug Abuse Screening Test (DAST) score of \\>2) or alcohol abuse (Alcohol Use Disorders Identification Test (AUDIT) score of \\> 7) within the last 6 months prior to screening\n12. Participants on a special diet, e.g., vegan, low-carbohydrate for intentional weight loss, ketogenic, low-FODMAP diet at the screening visit, or plan for such diet during the study duration\n13. Employees and\u002For children\u002Ffamily members or relatives of employees of Danone or the study team members (dependent relationship with study team members) participating sites such as, employees of the Investigator or of the Sponsor, members of the armed forces, and persons kept in detention\n14. Participant expected to be living in the same home as a current participating participant and to concomitantly receive SP",true,"ALL","40 Years","65 Years",{"count":22,"type":23},100,"ESTIMATED","INTERVENTIONAL",[26],"NA","The DORA study is a single-arm, open-label, interventional exploratory study designed to evaluate the impact of a synbiotic-containing senior milk powder on the gut microbiome and selected biological, physiological, and digital health parameters in community-living adults in good health.\n\nThe study enrolls adults aged 40 to 65 years and aims to investigate changes in gut microbial composition, with a primary focus on butyrate-producing microbial taxa, following at least 28 days of study product consumption. Secondary and exploratory objectives include assessment of stool metabolites, blood-based biomarkers, bowel patterns, sleep quality, physical activity, cognitive function, dietary patterns, and quality of life.\n\nApproximately 125 participants will be recruited in Singapore to achieve 100 study completers. Following informed consent and screening, participants undergo a baseline observation period of 14 days during which physiological and lifestyle data are collected using wearable digital health devices. Baseline assessments also include blood sampling, stool collection for microbiome analysis, digital imaging and videography, and completion of validated questionnaires.\n\nAfter completion of baseline assessments and collection of the first stool sample, participants initiate consumption of the study product, a senior milk powder containing a defined synbiotic formulation. The study product is consumed twice daily for a minimum of 28 days and up to 35 days to allow completion of study assessments.\n\nParticipants return for end-of-intervention assessments following the study product phase, including repeat biological sampling, physical and digital assessments, and questionnaires. Stool microbiome profiles and other exploratory outcomes are compared between baseline and post-intervention time points.\n\nThis exploratory study is intended to generate feasibility data and hypotheses regarding the effects of synbiotic nutritional intervention and the integration of biological and digital health data in the context of healthy aging.",[29,30,31],"Healthy Adult Participants","Gut Microbiomes","AI",[33,34,35,36,37,38,39,40,41],"Healthy Aging","Gut Microbiome","Gut Health","Probiotics","Prebiotics","Nutritional Intervention","Microbiome Profiling","Digital Health","Wearable Devices","NOT_YET_RECRUITING","2026-05-07",{"date":45,"type":46},"2026-05-12","ACTUAL",{"date":48,"type":23},"2026-04-27",{"date":50,"type":23},"2027-03-31",{"name":52,"class":53},"Danone Asia Pacific Holdings Pte, Ltd.","INDUSTRY",{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":17,"sex":18,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":24,"phases":65,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100621086","autologous-probiotics-in-patients-with-defunctioning-ileostomy-following-lar-for-rectal-cancer-100621086","NCT07366047","Autologous Probiotics in Patients With Defunctioning Ileostomy Following LAR for Rectal Cancer","The Safety and Efficacy of Autologous Probiotics in Patients With Defunctioning Ileostomy Following Low Anterior Resection for Rectal Cancer.","Inclusion Criteria:\n\nAge: 18-80years old; Curative low anterior resection for rectal cancer with defunctioning ileostomy; ileostomy closure within 3-6 month; Preoperative chemoradiotherapy ; No evidence of anastomotic leakage or severe stenosis\n\nExclusion Criteria:\n\nTumor recurrence or distant metastasis; Secondary operation with stoma; Prior disease impairing bowel function except for rectal cancer; Any contraindication for transanal irrigation; Pregnant or nursing; Serious cardiovascular disease, uncontrolled infections, or other serious uncontrolled concomitant disease; Cognitive or psychological disorder;","18 Years","80 Years",{"count":64,"type":23},40,[26],"Rectal cancer patients who received low anterior resection combined with ileostomy may effectively reduce the probability of anastomotic leakage after surgery. However, due to the long-term semi-abandoned state of the distal colon, the probability of bowel dysfunction after ileostomy closure is very high. The incidence of low anterior resection syndrome (LARS) exceeds 70%, which is twice that of those who did not receive a preventive stoma. The main reasons include postoperative anatomical structure alteration, nerve damage, pathological changes of the colorectal mucosa, and gut microbiota variation, etc. The application of probiotics can significantly improve the bowel function of these patients. In this study, in order to enhance the colonization effect of probiotics, autologous probiotics will be applied to treat patients with defunctioning ileostomy. The primary outcome is the occurrence of major LARS after 6 months of the treatment.",[68,30,69,70],"Rectal Cancer","Autologous Probiotic Transplantation","Defunctioning Ileostomy","2026-01-18",{"date":73,"type":46},"2026-01-26",{"date":75,"type":23},"2025-12-31",{"date":77,"type":23},"2027-12-31",{"name":79,"class":80},"Peking University Cancer Hospital & Institute","OTHER",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100580153","antimicrobial-combination-therapy-for-treatment-of-enterococcus-faecalis-bacteremia-100580153","NCT06833593","Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia","Efficacy of Optimized Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia and Identification of Intestinal Microbiota Signature","MicroEFfAECT","Inclusion Criteria:\n\n* Adult (≥18 years)\n* Monomicrobial EF-BSI\n* Receipt of ≥ 5 days of at least one in vitro active drug (ampicillin, amoxicillin\u002Fclavulanate, ampicillin\u002Fsulbactam, piperacillin, vancomycin, teicoplanin, daptomycin and linezolid) with or without a synergistic drug (ceftriaxone, gentamycin, streptomycin), at common suggested dosages for EF-BSI in empirical or definitive therapy\n* Written informed consent\n\nExclusion Criteria:\n\n* Short term (within 3 days from BSI) mortality\n* Other concomitant infection",{"count":90,"type":23},510,"OBSERVATIONAL","Prospective, multicenter, national, observational pharmacological study on the evaluation of efficacy of appropriate monotherapy vs combination treatment for non-complicated Enterococcus faecalis (EF) bloodstream infection (BSI) and identification of gut microbiota fingerprint of patients with EF-BSI correlated to antimicrobial treatment and clinical outcome",[94,95,30],"Enterococcus Faecalis Infection","Blood Stream Infection",[97,98,99,100],"Enterococcus faecalis bloodstream infection","Human tissue analysis in vitro","Gut microbiota analysis","Enterococcus faecalis genomic analysis","RECRUITING","2025-11-26",{"date":104,"type":46},"2025-12-03",{"date":106,"type":46},"2021-02-06",{"date":108,"type":23},"2026-09-26",{"name":110,"class":80},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",4,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":18,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":122,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100589794","therapeutic-strategies-for-type-2-diabetes-based-on-lifestyle-changes-plant-based-diet-and-physical-exercise-100589794","NCT06959043","Therapeutic Strategies for Type 2 Diabetes Based on Lifestyle Changes: Plant-based Diet and Physical Exercise","Inclusion Criteria:\n\n* Have a medical diagnosis of type 2 diabetes for a maximum of 5 years.\n* Be omnivorous; Have a Body Mass Index (BMI) ≥ 25 kg\u002Fm2 and \\\u003C 40 kg\u002Fm2;\n* Be between the ages of 45 and 70, both genders.\n* Women should be in the postmenopausal stage;\n* Use no more than three hypoglycemic medications in total;\n* Have the availability for a four-week consecutive hospitalization at CSVN.\n\nExclusion Criteria:\n\n* Be using insulin, anti-obesity medications, antibiotics, and\u002For probiotic supplements in the 2 months preceding data collection;\n* Use of alcohol or tobacco;\n* Have limited mobility and a previous diagnosis of cardiopulmonary diseases;\n* Report current or previous (within the past two months) diarrhea during screening;\n* Have liver or kidney failure and uncontrolled endocrine disorders (hypothyroidism, hypogonadism, and adrenal insufficiency);\n* Have eating disorders or have undergone bariatric surgery.","45 Years","70 Years",{"count":121,"type":23},60,[26],"The study evaluates the impact of a strict vegetarian diet combined with regular physical exercise and the use of probiotics on metabolic, inflammatory, and epigenetic parameters in patients with type 2 diabetes. It aims to determine the influence of these interventions on gut microbiota, glycemic control, body composition, insulin resistance, and quality of life.",[125,126,127,30],"Type 2 Diabetes Mellitus (T2DM)","Insulin Resistance","Inflamation",[129,126,127,130,131,34,132,133],"Type 2 Diabetes Mellitus","Metabolic Syndrome","Physical Exercise","Plant-based Diet","Lifestyle Interventions","2025-05-13",{"date":136,"type":46},"2025-05-18",{"date":138,"type":46},"2022-11-22",{"date":140,"type":23},"2026-12",{"name":142,"class":80},"Maria Elizabeth Rossi da Silva",1,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":24,"phases":154,"briefSummary":156,"conditions":157,"keywords":163,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":143},"100570694","phase-4-multimodal-image-technologies-investigate-the-role-and-mechanism-of-probiotics-in-improving-rbd-with-parkinsons-disease-100570694","NCT06710574","Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving RBD with Parkinson's Disease","Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving Rapid Eye Movement Behavior Disorder with Parkinson's Disease","Inclusion Criteria:\n\nInclusion criteria for PD-RBD patients:\n\n* Age between 40 and 80 years, both males and females\n* Patients with idiopathic Parkinson's disease, meeting the MDS clinical diagnostic criteria for Parkinson's disease (2015)\n* Modified Hoehn and Yahr stage of Parkinson's disease ≤ stage 3\n* No dementia, with a Mini-Mental State Examination (MMSE) score \\> 24\n* No depression or anxiety, as indicated by Hamilton Depression Scale score \\\u003C 9 and Anxiety Scale score \\\u003C 14\n* Rapid Eye Movement Sleep Behavior Disorder (RBD) screening questionnaire score \\> 5, diagnosed with RBD based on polysomnography results, and exclusion of obstructive sleep apnea\n* Stable condition of Parkinson's disease motor symptoms and RBD symptoms in the month prior to enrollment, with no adjustments to Parkinson's disease medications in the month prior to enrollment\n* Discontinuation of benzodiazepines such as clonazepam and melatonin in the month prior to enrollment\n* No use of probiotics, prebiotics (including lactulose), or antibiotics for the two months prior to enrollment, if used, a two-month washout period should be observed\n* Understanding and willingness to comply with the study protocol, agreeing to participate, and signing the informed consent form.\n\nInclusion criteria for iRBD patients:\n\n* Age between 40 and 80 years, both males and females\n* Rapid Eye Movement Sleep Behavior Disorder (RBD) screening questionnaire score \\> 5, diagnosed with RBD based on polysomnography results, and exclusion of obstructive sleep apnea or restless legs syndrome\n* No dementia, with a Mini-Mental State Examination (MMSE) score \\> 24\n* No depression or anxiety, as indicated by Hamilton Depression Scale score \\\u003C 9 and Anxiety Scale score \\\u003C 14\n* Discontinuation of benzodiazepines such as clonazepam and melatonin in the month prior to enrollment\n* No use of probiotics, prebiotics (including lactulose), or antibiotics for the two months prior to enrollment, if used, a two-month washout period should be observed\n* Understanding and willingness to comply with the study protocol, agreeing to participate, and signing the informed consent form.\n\nInclusion criteria for healthy subjects\n\n* Age between 40 and 80 years, age and gender matched with the above two groups of patients\n* Rapid Eye Movement Sleep Behavior Disorder screening questionnaire score ≤ 5, exclusion of RBD or obstructive sleep apnea based on polysomnography results\n* No dementia, with a Mini-Mental State Examination (MMSE) score \\> 24.\n* No depression or anxiety, as indicated by Hamilton Depression Scale score \\\u003C 9 and Anxiety Scale score \\\u003C 14\n* No severe constipation, not meeting the diagnostic criteria for Rome III chronic constipation; No use of probiotics, prebiotics (including lactulose), or antibiotics for the two months prior to enrollment, if used, a two-month washout period should be observed\n* Understanding and willingness to comply with the study protocol, agreeing to participate, and signing the informed consent form.\n\nExclusion Criteria:\n\nPD-RBD exclusion criteria:\n\n* Parkinsonism plus syndrome and secondary parkinsonism such as multiple system atrophy, progressive supranuclear palsy, cortical basal ganglia degeneration, dementia with Lewy bodies, vascular parkinsonism, post-encephalitis parkinsonism, or any other non-primary parkinsonism\n* Taking any probiotics or prebiotics (including lactulose) or antibiotics within 2 months before enrollment\n* Adjustment of Parkinson's disease medication within 1 month before enrollment; In group 1 month before taking clonazepam and benzodiazepines medicine melatonin, etc.\n* With the following diseases such as Alzheimer's disease, malignant tumor, spinal cord lesions, epilepsy, autonomic nerve disease (urinary retention, urinary incontinence or orthostatic hypotension, vertical drop in blood pressure in five minutes more than 30\u002F15 MMHG), etc.; New onset of cerebrovascular disease or severe sequelae of cerebrovascular disease within 3 months, affecting the assessment\n* Patients with anxiety or depression and taking medication\n* Serious cardiovascular diseases (such as the American heart association heart function class for Ⅲ - Ⅳ of congestive heart failure, the 6 month history of myocardial infarction, etc.)\n* Severe liver and kidney dysfunction, cereal third transaminase, aspertate aminotransferase, total bilirubin is higher than the upper limit of normal value of 1. 5 times; Serum creatinine is higher than the upper limit of normal value 1. 5 times\n* Pregnant and lactating women or pregnant women aged 40-60 years with positive HCG;\n* Known to be allergic to Bifidobacterium triple viable capsules, Bacillus licheniformis, or their excipients\n* Has a history of history of drug abuse or alcohol dependence\n* Were enrolled in another clinical trial at enrollment\n* Refusal to participate in the study or inability to cooperate with the study investigator; The researchers judgment for doesn't fit into the group of patients.\n\nExclusion criteria for iRBD:\n\n* PD motor symptoms and parkinsonism were included in the PD-RBD group; \"Parkinsonism plus syndrome and secondary parkinsonism, such as multiple system atrophy, progressive supranuclear palsy, cortical basal ganglia degeneration, dementia with Lewy bodies, vascular parkinsonism, post-encephalitis parkinsonism, or any other non-primary Parkinson's disease;\"\n* Into the group 2 months before taking any probiotics and prebiotics (including lactulose) or antibiotics\n* Adjustment of Parkinson's disease medication within 1 month before enrollment; In group 1 month before taking clonazepam and benzodiazepines medicine melatonin, etc.\n* With the following diseases, including but not limited to obstructive sleep apnea syndrome, Alzheimer disease, malignant tumor, spinal cord lesions, epilepsy, autonomic nerve disease (urinary retention, urinary incontinence or orthostatic hypotension, vertical drop in blood pressure in five minutes more than 30\u002F15 MMHG), etc.; 3 month new cerebrovascular disease or severe cerebrovascular disease sequela, impact assessment;\n* Patients with severe anxiety or depression or under drug treatment;\n* Severe cardiovascular diseases (such as congestive heart failure with American Heart Association functional class Ⅲ-Ⅳ, history of myocardial infarction within 6 months, etc.);\n* Severe liver and kidney dysfunction, cereal third transaminase, aspertate aminotransferase, total bilirubin is higher than the upper limit of normal value of 1. 5 times; The serum creatinine was higher than the upper limit of the normal range. 5 times;\n* Pregnant and lactating women or pregnant women aged 40-60 years with positive HCG;\n* Known to be allergic to Bifidobacterium triple viable capsules, Bacillus licheniformis, or their excipients;\n* With a history of drug abuse or alcohol dependence\n* Were enrolled in another clinical trial at enrollment;\n* Refused into groups, and can cooperate with researchers; Patients who were judged by the investigator to be ineligible for enrollment.\n\nHealthy subjects exclusion criteria:\n\n* Patients with Parkinson's disease motor symptoms and met the diagnosis of parkinsonism were included in PD-RBD group; \"Parkinsonism plus syndrome and secondary parkinsonism, such as multiple system atrophy, progressive supranuclear palsy, cortical basal ganglia degeneration, dementia with Lewy bodies, vascular parkinsonism, post-encephalitis parkinsonism, or any other non-primary Parkinson's disease;\" 2) taking any probiotics or prebiotics (including lactulose) or antibiotics within 2 months before enrollment; 1 month before the 3) into the group of Parkinson's disease medication adjustment; Benzodiazepines such as clonazepam and melatonin were taken within 1 month before enrollment. 4) combined with the following diseases, including but not limited to obstructive sleep apnea syndrome, Alzheimer's disease, malignant tumors, spinal cord lesions, epilepsy, autonomic disorders (urinary retention, urinary incontinence or orthostatic hypotension, blood pressure drop more than 30\u002F15 MMHG after 5 minutes of standing), etc.; New onset of cerebrovascular disease or severe sequelae of cerebrovascular disease within 3 months, affecting the assessment\n* Patients with severe anxiety or depression or under drug treatment;\n* Severe cardiovascular diseases (such as congestive heart failure with American Heart Association functional class Ⅲ-Ⅳ, history of myocardial infarction within 6 months, etc.)\n* Severe liver and kidney dysfunction, cereal third transaminase, aspertate aminotransferase, total bilirubin is higher than the upper limit of normal value of 1. 5 times; The serum creatinine was higher than the upper limit of the normal range. 5 times\n* Pregnant and lactating women or pregnant women aged 40-60 years with positive HCG; 9) known to the bifidobacterium triple viable capsules, bacillus licheniformis, or its accessories, and other allergies;\n* With a history of drug abuse or alcohol dependence\n* Were enrolled in another clinical trial at enrollment;\n* Refused into groups, and can cooperate with researchers; The researchers judgment for doesn't fit into the group of patients.","85 Years",{"count":153,"type":23},120,[155],"PHASE4","Rapid eye movement sleep behavior disorder (RBD) is important non-movement feature, and also the important risk factor of Parkinson's disease (PD). In our previous work, we found that the movement features and RBD of PD patients improved after taking probiotics. The later was not reported before and the mechanism not clear. To investigate its role and mechanism, we plan to enroll patients of PD-RBD, idiopathic RBD, and healthy control, collect data of multimodal image technology before and after probiotic treatment，including resting state functional MRI，1H-MRS，123I-MIBG; analyze these data with clinical features, including UPDRS -III score, RBD-HK score , as well as the bacteria abundance and level of glutamate，GABA in blood and stool. Then, construct PD mouse model by fecal transplantation of PD patient, give or not give mouse probiotics treatment, and detect the level of glutamate, GABA, and so on, as well as α-synuclein of each brain area of each group, to explore the role and mechanism of probiotics in improving RBD and movement disorder of PD.",[158,159,160,30,161,162],"Parkinson Disease","Movement Disorders","Rapid Eye Movement Sleep Behavior Disorder","Magnetic Resonance Imaging (MRI)","Probiotic",[162,164,160,165],"Parkinson's disease","Multimodel Magnetic Resonance Imaging","2024-11-29",{"date":168,"type":46},"2024-12-02",{"date":170,"type":46},"2022-09-01",{"date":172,"type":23},"2025-06-30",{"name":174,"class":80},"Beijing Friendship Hospital"]